Zydus Lifesciences Q3 FY24 PAT up 26.8%

Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.

Lupin launches Varenicline Tablets in US

Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US

Lupin launches liquid fibre Softovac Liquifibre

Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients

JB Pharma buys opthalmology brands from Novartis for Rs 964 Cr

JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market

Lupin receives tentative approval from USFDA for Canagliflozin Tablets

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor

Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’

Yesafili, received marketing authorization approval from the European Commission for the European Union

SMS Pharmaceuticals reports robust Q2FY24 operational performance

Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets

This product will be manufactured at Lupin’s Pithampur facility in India

Glenmark to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 diabetes

Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually